Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Ocul Immunol Inflamm. 2021 Aug 18;29(6):1126-1131. doi: 10.1080/09273948.2020.1726970. Epub 2020 Mar 6.
: To report the outcomes in eyes with noninfectious uveitis receiving dexamethasone implant at the time of pars plana vitrectomy (PPV).: Retrospective analysis of visual acuity (VA), intraocular pressure (IOP), vitreous haze score (VHS), and central subfield thickness (CST) at baseline and follow-up visits.: Fourteen eyes received dexamethasone implant at the time of PPV. The CST was improved from 469 ± 182 µm at baseline to 320 ± 60 at 6 months ( = .0112) and 295 ± 46 at 12 months ( = .0728). Vitritis only recurred in 2 eyes at 6 months (18.2%) and 1 eye at 12 months (14.3%). The probability of VA improvement of ≥0.3 logMAR was 57% at 6 months and 66% at 12 months. Therapy for IOP rise was initiated in 6 eyes (42.9%).: Local delivery of dexamethasone implant with PPV is a feasible method to counteract postoperative inflammation and macular thickening.
: 报告在接受经睫状体平坦部玻璃体切除术（PPV）时植入地塞米松植入物的非感染性葡萄膜炎眼的结果。: 对视力（VA）、眼内压（IOP）、玻璃体混浊评分（VHS）和中央眼底厚度（CST）在基线和随访时进行回顾性分析。: 14 只眼在接受 PPV 时接受了地塞米松植入物。CST 从基线时的 469 ± 182 µm 改善至 6 个月时的 320 ± 60 µm（ =.0112）和 12 个月时的 295 ± 46 µm（ =.0728）。仅在 6 个月（18.2%）和 12 个月（14.3%）时 2 只眼出现眼内炎复发。VA 改善≥0.3 logMAR 的概率在 6 个月时为 57%，在 12 个月时为 66%。6 只眼（42.9%）开始进行 IOP 升高的治疗。: PPV 联合地塞米松植入物局部给药是对抗术后炎症和黄斑增厚的可行方法。
